Navigation Links
VIA Pharmaceuticals Announces Grant of New Patent on Lead Compound VIA-2291
Date:2/25/2009

tients for the FDG-PET clinical trial, as well as any future clinical trial; -- failure to obtain sufficient data from enrolled patients that can be used to evaluate VIA-2291, thereby impairing the validity or statistical significance of our clinical trials; -- our ability to successfully complete our clinical trials of VIA- 2291 on expected timetables and the outcomes of such clinical trials; -- complexities in designing and implementing cardiovascular clinical trials using histological examinations, measurement of biomarkers, medical imaging and atherosclerotic plaque bioassays; -- the results of our clinical trials, including without limitation, with respect to the safety and efficacy of VIA-2291; -- if the results of the ACS and CEA studies, upon further review and analysis, are revised or negated by authorities or by later stage clinical trials; -- our ability to obtain necessary FDA approvals; -- our ability to successfully commercialize VIA-2291; -- our ability to obtain and protect our intellectual property related to our product candidates; -- our potential for future growth and the development of our product pipeline, including the THR beta agonist candidate and the other compounds licensed from Roche; -- our ability to form and maintain collaborative relationships to develop and commercialize our product candidates; -- general economic and business conditions; and -- the other risks described under Item IA "Risk Factors" in our Annual Report on Form 10-K for the fiscal year ended December 31, 2007 and in our Quarterly Report on Form 10-Q for the fiscal quarter ended September 30, 2008 on file with the SEC.

All forward
'/>"/>

SOURCE VIA Pharmaceuticals, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. Vion Pharmaceuticals Pays Interest on 7.75% Convertible Senior Notes
2. China Biopharmaceuticals Holdings Announces Second Quarter 2007 Financial Results
3. Vion Pharmaceuticals Completes Accrual of 85 Patients to its Pivotal Phase II Trial of Cloretazine(R) (VNP40101M) in Elderly AML
4. XTL Biopharmaceuticals Announces Financial Results for the Six Months Ended June 30, 2007
5. Cadence Pharmaceuticals Reports Second Quarter 2007 Financial Results
6. Nabi Biopharmaceuticals to Present at Upcoming Industry Conferences
7. Anadys Pharmaceuticals Appoints Steve Worland, Ph.D. as President and Chief Executive Officer
8. Poniard Pharmaceuticals Announces Participation in Upcoming Conferences
9. NovaQuest Advances Virtual Development Model With Strategic Investment in TOPIGEN Pharmaceuticals
10. Drug Royalty Corporation (DRC) Announces Acquisition Regarding PEG-INTRON(R) From Enzon Pharmaceuticals, Inc. (ENZN)
11. Sunesis Pharmaceuticals Announces Reorganization to Focus Resources and Build Value in Clinical-Stage Programs
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/30/2014)... D.C., September 30, 2014 Applying a well-known ... researchers at Harvard University has demonstrated the ability ... -- work that holds promise for making future, ... detailing the sides of next-gen rocket ships and ... light passes through oil in water, it becomes ...
(Date:9/30/2014)... NEW YORK , Sept. 30, 2014 /PRNewswire/ ... trends and segments with highest potential revenues Do ... Visiongain,s updated report gives you revenue predictions for ... ahead. For those therapies you find financial data, ... new analysis you get sales forecasts to 2024 ...
(Date:9/30/2014)... Proove Biosciences , the commercial and ... a new genetic test built upon research from their ... will provide physicians with an objective way to ... are stratified between individuals. With this new test, physicians ... a genetic predisposition that will affect their pain tolerance. ...
(Date:9/30/2014)... 2014 Fast, semi-automatic creation ... in documents ChemAxon , a ... services for life science research, launches ChemCurator, an ... structures from documents. Markush structures are ... generating and understanding Markush structures is a difficult ...
Breaking Biology Technology:Taking thin films to the extreme 2Biosimilars and Follow-On Biologics: World Industry and Market Prospects 2014-2024 2Biosimilars and Follow-On Biologics: World Industry and Market Prospects 2014-2024 3Biosimilars and Follow-On Biologics: World Industry and Market Prospects 2014-2024 4Biosimilars and Follow-On Biologics: World Industry and Market Prospects 2014-2024 5Proove Biosciences is Now Offering the Proove Pain Perception Genetic Test to Help Physicians Assess Patient Pain Tolerance Levels 2Proove Biosciences is Now Offering the Proove Pain Perception Genetic Test to Help Physicians Assess Patient Pain Tolerance Levels 3ChemAxon Introduces ChemCurator for Chemical Information Extraction and Markush Structure Creation 2
... Auxogyn, Inc., a privately held medical technology company ... acquired an exclusive license from Stanford University to develop ... in the field of assisted reproduction to significantly improve ... procedures. The technology licensed from Stanford is ...
... Calif., Oct. 4 Dainippon Sumitomo Pharma Co., Ltd. ... have entered into an option agreement to co-develop a ... the agreement, DSP has received an option for exclusive ... a promising cell therapy drug candidate being developed by ...
... BOTHELL, WA and VANCOUVER, Oct. 4 /PRNewswire-FirstCall/ - OncoGenex Pharmaceuticals, ... of OncoGenex will present at the 9th Annual BIO Investor ... The Palace Hotel in San Francisco, CA. Live ... Relations page of the OncoGenex Web site at http://ir.oncogenex.com ...
Cached Biology Technology:Auxogyn Licenses Non-invasive Embryo Assessment Technology From Stanford University 2Dainippon Sumitomo Pharma and SanBio Collaborate on Cell Therapy for Stroke Recovery 2OncoGenex Pharmaceuticals to Present at the 9th Annual BIO Investor Forum 2
(Date:9/30/2014)... news release is available in German . ... in their behavioural response to risky situations such as ... for Ornithology now found in a long-term study on ... with both metabolic rate and ambient temperature. High metabolic ... behaviour, as in these scenarios birds were more likely ...
(Date:9/30/2014)... threats in today,s ocean. From overfishing and pollution ... ecosystems are disappearing at unprecedented rates around the ... surrounding the island of Moorea in French Polynesia ... coral guard-crabs. New research from the National Museum ... McKeon and the museum,s predoctoral fellow Jenna Moore ...
(Date:9/30/2014)... 2014 Winners of The Economist,s prestigious Innovation ... to take place at the JW Marriott Hong Kong on Friday, ... will share their experiences and the lessons those hold for others. ... innovation over the past decade, will be presented at a ceremony ... summit. It will be the first time the ceremony has come ...
Breaking Biology News(10 mins):Risky metabolism 2Smithsonian scientists discover coral's best defender against an army of sea stars 2Hear from The Economist's 2014 Innovation Award Winners at Innovation Summit on October 10th in Hong Kong 2Hear from The Economist's 2014 Innovation Award Winners at Innovation Summit on October 10th in Hong Kong 3Hear from The Economist's 2014 Innovation Award Winners at Innovation Summit on October 10th in Hong Kong 4Hear from The Economist's 2014 Innovation Award Winners at Innovation Summit on October 10th in Hong Kong 5Hear from The Economist's 2014 Innovation Award Winners at Innovation Summit on October 10th in Hong Kong 6Hear from The Economist's 2014 Innovation Award Winners at Innovation Summit on October 10th in Hong Kong 7
... , A scientist from Nanyang Technological University (NTU) may be ... a little sea creature called the mantis shrimp. The ... preferred material for medical implants and military body armour ... Science , the world,s top scientific journal, and focused ...
... high-resolution image of a palm tree in Brazil, which ... on nectars and pollens, was the top jury selection ... GigaBlitz. It,s also an example of what organizers hope ... The Nearby Nature GigaBlitz events are citizen science ...
... coastal restoration, The Nature Conservancy and a team of scientists ... led by the University of Cambridge conducted an in-depth study ... actual biomass (the "living weight") of oyster reefs in dozens ... ecology with real numbers, published today in Proceedings of ...
Cached Biology News:NTU researchers study little mighty creature for scientific breakthrough 2NTU researchers study little mighty creature for scientific breakthrough 3Citizen scientists to document biodiversity with high-resolution imagery during summer solstice 2New report puts real numbers behind history of oyster reefs 2
... Asb-2 (Ankyrin repeat and SOCS box-containing protein) ... peptides containing amino acids 75-93 and 348-368 ... (Imgenex Catalog No. 40149) can be used ... react with mouse and rat Asb-2, based ...
... Rabbit polyclonal to ErbB 2 ... Abpromise for all tested applications). ... peptide: AENPEYLGLDVPV conjugated to KLH, corresponding ... of Human c-ErbB2 ...
SHP-2 Antibody...
Sheep polyclonal to ErbB 2 ( Abpromise for all tested applications). Antigen: Recombinant full length c-ErbB2 protein (Human). Entrez GeneID: 2064 Swiss Protein ID: P04626...
Biology Products: